Tokyo, Japan., Dec 26, 2013 – REGiMMUNE Corporation (RGI) today announced that the Company has appointed Mr. Kenzo Kosuda to the position of senior vice president, chief financial officer (CFO), and a member of the board effective as of Today. Mr. Kosuda has spent the over 20 years in various CFO positions for companies including Sparx Asset Management where he led the first IPO of an asset management company in Japan.
“Kenzo is a great addition to our management team. His depth of experience in managing financial reporting for public companies as well as his proven ability to negotiate and structure transactions will be invaluable to RGI” stated Haru Morita , president and chief executive officer of RGI.
“I am thrilled to join RGI at this point in the company’s journey,” stated Mr. Kosuda. “RGI has a strong leadership team that is committed to develop novel products to its potential patients. Significant progress has been made over the past years to develop its leading program, RGI-2001, as well as following programs. I look forward to participating in continued value creation for patients and contributing to the corporate development of REGiMMUNE when it advance to the next stage.”
Mr. Kenzo Kosuda served as CFO of SPARX Asset Management Co., Ltd., which he led to go public in 2001. Prior to Sparx, he was a financial manager at Toyo Trust Bank (which later merged into Mitsubishi UFJ Trust and Banking) and Tohmatsu & Co.,(now a part of Deloitte Touche Tohmatsu LLC). He also had experience to run his own accounting/consulting firm where he helped many emerging companies in Japan. Mr. Kosuda has an BA degree in Economics from the Keio University in Japan and is a Chartered Accountant.
REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The company’s proprietary platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. Using its reVax technology, REGiMMUNE is developing RGI-2001, which may be the first drug in the class of Treg-inducing agents.
The company is also applying its reVax technology to develop a range of pipeline products, including its RGI-1000 series for allergy and its RGI-3100 series for type 1 diabetes. Additionally REGiMMUNE is developing its RGI-4000 series for vaccine adjuvants. The company is seeking pharmaceutical partnership opportunities for its products worldwide, exclusive of Japan. REGiMMUNE is headquartered in Tokyo, Japan and has a U.S. operation in Santa Clara, California
For more information about REGiMMUNE, please contact us.